Australia's Dimerix climbs on patient dosing to test COVID-19 drug in India

Dimerix

11/01/2022 02:37

** Drug developer's shares  DXB.AX  rise as much as 5.7% to
A$0.28, highest since Oct. 27
    ** Company says first patients have been dosed in India as
part of a study for its drug DMX-200 as a potential new
treatment for respiratory complications associated with COVID-19
 urn:newsml:reuters.com:*:nASX4cbzkk
    ** Dimerix says multiple sites in India have been given
regulatory approval for study and shipment of DMX-200 to the
country from U.S.-based manufacturer
    ** Company's shares on track for biggest intraday pct gain
since Jan. 4
    ** More than 679,000 shares change hands vs 30-day avg
volume of ~496,600 shares
    ** Stock up 4.3% in 2021

 (Reporting by Roushni Nair in Bengluru)
 ((Roushni.Nair@thomsonreuters.com))